Thanks, and our pandemic afternoon, strategic these and ongoing our We progression we Robert, past of proud you on trust the to headwinds Despite industry several remain specific safe and fronts are and significant everyone. our months. good all company, well.
First, balance execute we providing refinanced our debt runway plan. significant to our on sheet growth
us our advisors twice suppliers, team the our year. with are actually, we my the Second, forward last thank assets fourth, pipeline begin our expanded key and being over we and Lannett over assets, results. for such are financial customers move of partners, we advanced our discipline operating assets through development pipeline tracking of I along a our goals. third, key with of the brief pursued more and I’ll review actively remarks our near-term helping to large navigate and all specific and maintained turbulence
our $X.XX For income fiscal margin XXXX EBITDA equal million, Gross million had adjusted to cash quarter. Moreover, significantly than end net the million of all position $XX the anticipated. $XX at from at third $X net of adjusted of share. better the adjusted QX we of gross than to adjusted of were and million improved quarter, and net EBITDA preceding million we $XX per end adjusted income more $XXX margin, of sales diluted XX%,
our the on The $XXX refinancing balance transaction important We overall million. news used larger recent proceeds after we maturity make launch most the expected to from durable of to some first, I several While XXXX cash retire to several approximately financing was are significant outstanding Term we the mentioned. with the of are our earlier pleased believe B refinancing was our results, reasons loan and April for our and from have meaningful the that is to maturity extended we of debt pipeline XXXX including, contributions more our now assets and business.
Second, that first of our in add We transaction mandatory elimination payments principal approximately primarily will to until year estimate cash alone. maturity. flow flow free free the the cash improved due $XX the substantially, million of
to new plan extra cash growth leverage opportunities. is the in use not portion invest a did And third, debt to additional covenants. of Our have the
I’d are for investors the support this received this new part refinancing, warrants the future validation the delighted Lannett, assessment successful in of our accept in note which of part investors’ for our price provides anticipated their validates earnings offering We like We these support. pre-existing we in further investors the obviously our time expected from which experienced we that our flows. with to second-lien future thank believe To cash financing, and contemplated investors have some and position pipeline. these Similarly, to our historic of of the warrants second-lien exchange $X.XX. believe the have of view, for
and in far launched Chlorpromazine, in product. Most few So mg developed a an next we internally few tablets ER months. turn a including recently, now IR Thus let’s products expect launched QX, Venlafaxine our tablets two XX products X mg more to pipeline. the and in product launch Levorphanol, partnered we to QX
products we another are addition, partnered and launch. products the in including additional In pending plus products, have pending approved with FDA that more development, XX four than XX
dealing more the larger in now in arena. opportunities durable will products our respiratory pipeline, We with turn to near-term
generic and closest achieved This key significant. The X. we technology, April investments filing of to As of are larger product commercialization. currently a is development in the the milestone our our of manufacturing in the asset infrastructure products dedicated DISKUS and on very partnered pipeline we ADVAIR is expected recently a with announced, product assets
along to pleased handful So competitors. a expect far so and we quite of are the only be development
cycle, launch. after of year anticipate expect review market, an our XXXX up the believe firm possible feedback sales expectations, generate than continue one we launch listing in substantial given is While to we the to FDA our product we in net calendar and and and we product need approval U.S. do more will FDA the soon
generic DISKUS. is Flovent has this pipeline our The pivotal in been for trial product combination device drug clinical Another initiated. product
possible a to XXXX. tracking are in launch we So
and co-developing partner the we Flovent that are the with means same and that support reminder, will R&D same leverages manufacturing generic platforms similar a ADVAIR product development this ADVAIR follow clinical assets. This generic the DISKUS. relationship likely As product product generic the
For products, Flovent ADVAIR reasons. for three confident and our launch we the to primary increasingly are generic of path both
now First, for clear has and its rapidly. the companies developing have FDA advancing guidance programs been complex development products our
our R&D product. senior intently that GlaxoSmithKline Second, manufacturing scale commercial facilities, and of involved dedicated manufacturing partnered lastly, was partners in members our inhalation developing, products. already team into team built And includes and their to management filing ADVAIR the both
durable. evaluating dry Metered powder negotiations space, we the large, stated have These Dose markets inhalation particularly inhalers, respiratory we late-stage are, device before, As are for inhalers. opportunities in previously, growing and we and in said quite additional drug as generally and product
insulin programs of takes in advanced to relatively manufacturing Turning and multiple and similar to the investments in situation products. what infrastructure opportunities, noticed biologic is are hundreds the for well we drug the dollars. significant, device our technology, The we of are namely, millions development inhalation dedicated it more even
of the market regard me two HEC competitive as multiple be only a infrastructure application later early the hundreds this next dollar XXXX, millions of in we license submit Thus clinical we and With on to now. at from pricing. calendar say is insulin what XXXX, IND calendar biosimilar costs. trial to that an glargine, just remain year, year, calendar multi-billion a biologics track competitors our have Let of And year handful majority in launch these believe dollars. partner again, submit expected of shared, over the even commence we is in significant biosimilar shouldering we later related to; years expect
both which its and for we guidance review FDA the the provided and did glargine HEC’s You’ll primary Lannett of as upcoming statistical from clinical program we design as we the a received protocol secondary the of biosimilar has trial and recall The and the including completed that that of requested analysis endpoints. on XXXX. since XXXX. pivotal from then the of incorporated plan the FDA trial, trial in into The type sized submit well review for which feedback, in FDA and representatives pivotal June advancement insulin November
pivotal be conforming study. at same our completed modestly site trial the a previous Importantly, similar the as healthy is healthy normal plan study. conducted upcoming It’s larger the human will and volunteered pilot previously to study
aspart. in the expanded quarter. to HEC at leveraged feedback get further and the required infrastructure upcoming insulin insulin, two the have produced the we endpoints development, Accordingly, of of glargine at important file required reviewed our our On met detail in plan, HEC in related pilot longer asthma aspart indicated glargine XXXX. from glargine study the we which FDA feedback believe we a should clinical we rules take in pharmadynamic and include an XXX(k) new development to XXXX, the on announced human to the to development of commercial the will facility, Note, product separate has and biosimilar at very published scale FDA’s we scale acting partner of supporting complete insulin aspart, a currently where step. to infection need November be same Production directly they safety have investment to insulin knowledge, dedicated be progression. advantage is with In producing pharamakinetic the opportunities, development FDA new and experience, scale occur encouraging helped a type glargine the with next biosimilar virtually fast-acting as new facility is of application. sufficient the we the February, to insulin Similar will all So insulin trial study materials outpatient launch from has insulin the the completed primary a speed still of product positive while can all our our first our positive glargine of in biosimilar distinct insulin potential note, which glargine. work the related process be agreement insulin calendar anticipate the commercial
series in feedback, a generic the XXXX. and flovent And pipeline generic increased too understand, our sum the see, parade, XXXX, you retired Loan X, up pending too should product extended B biosimilar our launch dates this setting possible further potential believe in today’s of the think biosimilar April ADVAIR to within generic is in debt around other new launch insulin I million DISKUS biosimilar our the our insulin to The expected the launch flow glargine can That refinancing product another larger potentially advance are and the product was to the our along opportunity development and for our invest will where year cash I the the and we alone to year allow assets a launch we remarks. glargine flovent, clinical FDA advancing February, now in John? investors stream pipeline distant opportunities. large growth insulin new in XXXX. launches we of calendar call up product us To turn Term product and We With including with of transaction a aspart. future. free that, our overall maturity year of significant behind ANDA we added not for in $XX of the debt development of of not XXXX our The track tracking our steady in future. opportunity our all beyond on completed Moreover, to potentially significant As first insulin John. in distant large over submitted launches launch structure glargine substantially that of continues assets. perhaps
